RESULTADOS INVESTIGACIÓN

Resultados: 118

02. CYP2C9

ECUADOR

Dorado P, Beltrán LJ, Machín E, Peñas-Lledó EM, Terán E, Llerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender. Pharmacogenomics. 2012 Nov;13(15):1711-7.

02. CYP2C9

ESTADOS UNIDOS

LLerena A, Dorado P, O’Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J. 2004;4(6):403-6.

02. CYP2C9

ESPAÑA

Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol. 2003 Jul;59(3):221-5.

Dorado P, Peñas-Lledó EM, González AP, Cáceres MC, Cobaleda J, Llerena A. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the 02. CYP2C9*3 allele. Fundam Clin Pharmacol. 2007 Aug;21(4):451-3.

Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong ML, Licinio J, Lares-Asseff I, Llerena A. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J. 2011 Apr;11(2):108-12.

García-Martín E, Martínez C, Ladero JM, Gamito FJ, Agúndez JA. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol. 2001 Apr;57(1):47-9.

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004 Aug;76(2):119-27.

López-Rodríguez R, Novalbos J, Gallego-Sandín S, Román-Martínez M, Torrado J, Gisbert JP, Abad-Santos F. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res. 2008 Jul;58(1):77-84.

02. CYP2C9

MÉXICO

Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong ML, Licinio J, Lares-Asseff I, Llerena A. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J. 2011 Apr;11(2):108-12.

Aguilar B, Rojas JC, Collados MT. Prevalence of CYP2C9 variants in the Mexican population. Arch Med Res. 2008 May;39(4):463.

Machorro-Lazo MV, Flores-Martínez SE, García-Zapién AG, Mújica-López KI, Morán Moguel MC, Sánchez-Corona J. Genetic frequency of the variant CYP2C9*2 in Western Mexican mestizos. HGM2003 Poster Abstracts. Genome Variation and Diversity.

Sosa-Macías M, Lazalde-Ramos BP, Galaviz-Hernández C, Rangel-Villalobos H, Salazar-Flores J, Martínez-Sevilla VM, Martínez-Fierro ML, Dorado P, Wong ML, Licinio J, LLerena A. Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics J. 2013 Dec;13(6):567-72.

02. CYP2C9

PORTUGAL

Branco CC, Pereirinha T, Cabral R, Pacheco PR, Mota-Vieira L. Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel’s healthy population (Azores). Thromb J. 2009 Jun 18;7:9.

Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics. 2007 Jul;8(7):703-12. doi: 10.2217/14622416.8.7.703.

02. CYP2C9

PUERTO RICO

Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Ruaño G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 6;411(17-18):1306-11.

03. CYP2B6

ARGENTINA

03. CYP2B6

COLOMBIA

Restrepo JG, Martínez C, García-Agúndez A, Gaviria E, Laguna JJ, García-Martín E, Agúndez JA. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics. 2011 Dec;21(12):773-8.

03. CYP2B6

ESPAÑA

Arenaz I, Vicente J, Fanlo A, Vásquez P, Medina JC, Conde B, González-Andrade  F, Sinués B. Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol. 2010 Apr;24(2):247-53.

03. CYP2B6

ESPAÑA

Oscarson M, Gullstèn H, Rautio A, Bernal ML, Sinués B, Dahl M-L, Stengaîrde JH, Pelkonenb O, Raunio H, Ingelman-Sundberg M. 1998. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Letters 438: 201-205.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies